PARIS and SPARTA: Finding the Achilles' heel of SARS-CoV-2

Viviana Simon  
*Icahn School of Medicine at Mount Sinai*

Ali H Ellebedy  
*Washington University School of Medicine in St. Louis*

et al

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Please let us know how this document benefits you.

**Recommended Citation**

Simon, Viviana; Ellebedy, Ali H; and et al, "PARIS and SPARTA: Finding the Achilles' heel of SARS-CoV-2."  
mSphere. 7, 3. e0017922 (2022).  
https://digitalcommons.wustl.edu/open_access_pubs/12061

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
PARIS and SPARTA: Finding the Achilles’ Heel of SARS-CoV-2


†Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA
‡The Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
§Center for Vaccine and Immunology, University of Georgia, Athens, Georgia, USA
¶Department of Infectious Diseases, University of Georgia, Athens, Georgia, USA
The authors declare a conflict of interest. The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays (inventors named FK, VS) and NDV-based SARS-CoV-2 vaccines (inventor named FK). FK would also like to note the following, which could be perceived as a conflict of interest: He has previously published work on influenza virus vaccines with S. Gilbert (University of Oxford), has consulted for Curevac, Merck and Pfizer (before 2020), is currently consulting for Pfizer, Seqirus, Third Rock Ventures and Avimex, his laboratory is collaborating with Pfizer on animal models of SARS-CoV-2, his laboratory is collaborating with N. Pardi at the University of Pennsylvania on mRNA vaccines against SARS-CoV-2, his laboratory was working in the past with GlaxoSmithKline on the development of influenza virus vaccines and two of his mentees have recently joined Moderna. RK reports consulting fees, honoraria, travel funding, and research support from GlaxoSmithKline and Perkin Elmer which manufactures SARS-CoV-2 testing and sequencing kits.

ABSTRACT To understand reinfection rates and correlates of protection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), we established eight different longitudinal cohorts in 2020 under the umbrella of the PARIS (Protection Associated with Rapid Immunity to SARS-CoV-2)/SPARTA (SARS SeroPrevalence And Respiratory Tract Assessment) studies. Here, we describe the PARIS/SPARTA cohorts, the harmonized assays and analysis that are performed across the cohorts, as well as case definitions for SARS-CoV-2 infection and reinfection that have been established by the team of PARIS/SPARTA investigators.

IMPORTANCE Determining reinfection rates and correlates of protection against SARS-CoV-2 infection induced by both natural infection and vaccination is of high significance for the prevention and control of coronavirus disease 2019 (COVID-19). Furthermore, understanding reinfections or infection after vaccination and the role immune escape plays in these scenarios will inform the need for updates of the current SARS-CoV-2 vaccines and help update guidelines suitable for the postpandemic world.

KEYWORDS COVID-19, SARS-CoV-2, antibodies, cohort study, reinfection

May/June 2022 Volume 7 Issue 3
10.1128/mSphere.00179-22
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 in China and has since caused the coronavirus disease 2019 (COVID-19) pandemic. Early reports from the Wuhan Institute of Virology indicated that individuals infected with this virus mounted antibody responses against it (1). Assays to measure these antibody responses were swiftly developed (2), and the general assumption was that antibodies, especially neutralizing antibodies, would correlate with protection and prevent reinfection. These assumptions were backed up by the detection of neutralizing antibodies after infection (3, 4) and the findings that prior infection protects nonhuman primates from reinfection (5, 6). Importantly, SARS-CoV-2 spike antibodies provided a correlate of protection in the nonhuman primate model (7, 8). However, reports of reinfections (9, 10), reports about waning of antibody within 8 weeks (11) (which turned out to be misleading), and studies suggesting reinfection with human seasonal coronaviruses (hCoVs) (12–14) highlight the need for large longitudinal observational studies to test these assumptions in a rigorous manner.

We established several longitudinal cohorts under the umbrella of the PARIS (Protection Associated with Rapid Immunity to SARS-CoV-2) and SPARTA (SARS SeroPrevalence And Respiratory Tract Assessment) studies to address the question of SARS-CoV-2 antibody durability and efficacy (e.g., protection against reinfection). These human cohorts were initially designed to compare the frequency of SARS-CoV-2 infection in seropositive to seronegative participants, thus pinpointing correlates of protection in the context of natural infection. With the rapid SARS-CoV-2 vaccine rollouts starting in mid-December 2020 in the United States, many of our cohorts also now track immune responses to vaccination in both seronegative and seropositive individuals at the time of immunization. These natural infection/vaccine cohorts will help to establish correlates of protection after natural infection and vaccination and inform about vaccine-induced immunity to newly emerging SARS-CoV-2 variants of interest/concern (15–20) (Fig. 1).

CONCEPT

The original PARIS cohort was planned and established at the Icahn School of Medicine at Mount Sinai in New York, NY, with the first participants being enrolled on 27 April 2020. During the following months, seven other cohorts were added to provide geographic diversity and achieve more statistical power (Table 1, Fig. 1). These cohorts were either preexisting (St. Jude, Washington University) or newly initiated. The overall concept for all cohorts was to follow individuals with and without prior COVID-19 by collecting data as well as biospecimens to measure immune responses (e.g., antibody responses to the spike protein of SARS-CoV-2) at least every 2 months. Molecular SARS-CoV-2 testing of symptomatic individuals to identify SARS-CoV-2, akin to phase III vaccine trials, was also included in each of the cohorts.

A shared theme of all eight cohorts was to enroll individuals who were at greater risk of COVID-19 in order to accumulate new infections faster. The initial PARIS study focused on health care workers (HCWs) in New York City, one of the early epicenters of the pandemic in the United States, but the other cohorts targeted other populations, including communities of color, first responders, and students. All cohorts used the same serological assay, which had originally been developed at Mount Sinai, to measure SARS-CoV-2 spike IgG antibodies (3, 21). This assay is an orthogonal enzyme-linked immunosorbent assay with high specificity and sensitivity which measures immune responses to the SARS-CoV-2 spike protein and therefore captures both infection- and vaccine-induced serum antibody responses (21). A detailed protocol for this assay has been published (21). However, as described below, many sites also collect saliva samples and perform molecular testing for not only SARS-CoV-2 but also other respiratory pathogens using multiplex diagnostic panels, and some cohorts sample and collect data at shorter (e.g., 2- or 4-week) intervals.

The eight PARIS/SPARTA cohorts are geographically distributed across the United States, covering the coasts (New York, NY, Los Angeles, CA, Miami, FL, Augusta, GA, Athens, GA) as well as the heartland (Memphis, TN, St. Louis, MO, Ann Arbor, MI). Collectively, these eight cohorts provide COVID-19-specific
information and biospecimens, at minimum, every 2 months for a total of 8,741 participants. While the primary analysis of antibody responses specific for each cohort is conducted by each site, a secondary analysis of the immune response data generated by the eight cohorts using the harmonized collection time points and assays will be performed by the common data analysis site established for the purpose of cross-cohort analysis and data modeling.

**DETAILED COHORT DESCRIPTIONS**

**PARIS (NYC).** This cohort follows health care workers from the Mount Sinai Health System in New York City (NYC). Immediate household members were also eligible for
<table>
<thead>
<tr>
<th>Cohort/location</th>
<th>Target enrollment (current enrollment)</th>
<th>Date of first enrollment</th>
<th>Sex, age, ethnicity distribution</th>
<th>Specimen and sampling intervals</th>
<th>Percent vaccinated</th>
<th>Percent boosted</th>
<th>No. of breakthrough infections after full vaccination</th>
<th>Principal investigator</th>
<th>Studies published</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACHILLES/St. Louis, MO</td>
<td>800 (671)</td>
<td>26 March 2020</td>
<td>49% female, Avg age, 54.5 yrs (range, 18.9–93.6), 49% white, 48% African-American</td>
<td>Serum, saliva, PBMCs 1/8 wks</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>Ali Ellebedy</td>
<td>22, 35, 41–44</td>
</tr>
<tr>
<td>SPARTA/St. Jude</td>
<td>1,315 (1,316)</td>
<td>23 April 2020</td>
<td>73% female, Avg age, 43.7 yrs (range, 20–83 yrs), 80% white, 20% African-American</td>
<td>Plasma, PBMCs 2 and 4 wks post event, then every 3 mo</td>
<td>91</td>
<td>NA</td>
<td>NA</td>
<td>Paul Thomas</td>
<td>36, 45–48</td>
</tr>
<tr>
<td>PARIS/New York City</td>
<td>400 (500)</td>
<td>27 April 2020</td>
<td>67% female, Avg age, 39 yrs (range, 18–74 yrs), 55% white, 45% African-American</td>
<td>Saliva, serum, plasma, PBMCs 2/4 wks</td>
<td>92</td>
<td>81</td>
<td>90</td>
<td>Viviana Simon, Florian Krammer</td>
<td>32–34, 37, 39, 40, 49–51</td>
</tr>
<tr>
<td>SPARTA/ Athens, GA</td>
<td>1,500 (1,833)</td>
<td>1 October 2020</td>
<td>69% female, Avg age, 44.7 yrs (range, 18–86), 86% white, 14% African-American</td>
<td>Saliva, serum, PBMCs 2/4 wks</td>
<td>74</td>
<td>42.9</td>
<td>236</td>
<td>Ted M. Ross</td>
<td>31, 52–54</td>
</tr>
<tr>
<td>SPARTA/ Augusta, GA</td>
<td>1,500 (637)</td>
<td>12 October 2020</td>
<td>62% female, Avg age, 45 yrs (range, 18–85), 49% white, 38% African-American</td>
<td>Saliva, serum, PBMCs 2/4 wks</td>
<td>55</td>
<td>15</td>
<td>NA</td>
<td>Ravindra Kolhe</td>
<td>55–59</td>
</tr>
<tr>
<td>PARIS/Miami, FL (CITY)</td>
<td>200 (228)</td>
<td>23 October 2020</td>
<td>60% female, Avg age, 48.2 yrs (range, 20–92), 84% white, 6% African-American, 38.5% Hispanic/LatinX</td>
<td>Serum, plasma, PBMCs 4/8 wks</td>
<td>87.2</td>
<td>50.8</td>
<td>31</td>
<td>Savita Pahwa</td>
<td></td>
</tr>
<tr>
<td>IASO/Ann Arbor, MI</td>
<td>5,000 (3,356)</td>
<td>29 October 2020</td>
<td>78.1% female, Avg age, 44.3 yrs (range, 18–94), 85.9% white, 14.1% African-American, 38.5% Hispanic/LatinX</td>
<td>Serum, PBMCs 8 wks</td>
<td>96.4</td>
<td>85.7</td>
<td>385</td>
<td>Aubree Gordon, Riccardo Valdez</td>
<td>60, 61</td>
</tr>
<tr>
<td>SPARTA/Los Angeles, CA</td>
<td>200 (200)</td>
<td>9 December 2020</td>
<td>70% female, Avg age, 40.2 yrs (range, 19–77), 16.5% white, 29% Asian, 40.5% Hispanic/LatinX</td>
<td>Saliva, serum, PBMCs 2/4 wks</td>
<td>83</td>
<td>32</td>
<td>23</td>
<td>Elaine Reed</td>
<td></td>
</tr>
</tbody>
</table>

*NA, Not applicable.
*Status as of 1 April 2022, not 28 February 2022.
participation. The first participants were enrolled on 27 April 2020. A total of 500 participants completed at least one study visit as of 28 February 2022, with 412 currently active participants (withdrawal rate, 18%). In total, 67% of participants are female, and the average age is 39 years (range: minimum [min], 18; maximum [max], 74 years); 55% of the participants self-identify as white, 14% as Asian, and 6% as African-American. In addition, 13% identify as Hispanic/LatinX. A total of 36% of the participants were sero-positive at enrollment, with the majority having been infected with SARS-CoV-2 in March/April of 2020 during the first pandemic wave when New York City emerged as one of the early epicenters of the pandemic in the United States. A total of 92% of the cohort has been fully vaccinated with mRNA vaccines (BNT162b2 [Pfizer] or mRNA-1273 [Moderna]), and 81% have received a booster vaccination (as of February 2022). A total of 90 PARIS participants tested positive for SARS-CoV-2 after being fully vaccinated (two doses of mRNA vaccines). At each study visit, saliva, serum, plasma, and peripheral blood mononuclear cells (PBMCs) are collected and cryopreserved. Nasopharyngeal swabbing is performed when participants report signs and symptoms suggestive of upper respiratory tract infections. Full-length spike binding IgG antibody concentrations are measured at each study visit.

IASO (PARIS/Ann Arbor, MI). The Immunity Associated with SARS-COV-2 (IASO) study follows staff and student employees at the University of Michigan, Ann Arbor. The first participant was enrolled on 29 October 2020, and as of 28 February 2021, 2,541 participants were active in the study, and enrollment is ongoing. To date, a total of 3,356 participants have ever been enrolled, 300 have withdrawn from the study (withdrawal rate, 8.9%), and 515 (15.3%) participants chose not to enroll in year 2. The average age of participants is 44.3 years (range: min., 18; max., 94 years), and 78.1% are female; 85.9% of the participants self-identify as white, 7.3% as Asian, 2.7% as African-American, 0.01% as Native Hawaiian or other Pacific Islander, 0.1% as American Indian or Alaska Native, and 2.0% as multiracial. In addition, 3.7% identified as Hispanic/LatinX. A total of 96.4% of the cohort was fully vaccinated as of 28 February 2021, and 85.7% had received a booster. Prior to vaccination, 62.8% of participants were SARS-CoV-2 naive, 9.6% were infected, 12.2% were vaccinated with an unknown infection history, and 3.0% were both vaccinated and infected, with timing of infection unknown; 0.5% of vaccinated participants were infected during the course of vaccination (between doses 1 and 2 or <14 days after dose 2), while 11.9% of vaccinated participants experienced a breakthrough infection (positive ≥14 days after dose 2). Of the 385 reported breakthrough infections, 284 (73.8%) were confirmed by PCR. Of study participants that are currently unvaccinated, 30.3% have no infection history and 69.7% have a history of at least one infection with SARS-CoV-2. At each study visit, serum is collected and cryopreserved. Asymptomatic serial respiratory samples and/or and peripheral blood mononuclear cells and plasma are collected from a subset of the cohort.

ACHILLES (PARIS/St. Louis, MO). The ACHILLES cohort comprises two study protocols enrolling participants at the Barnes-Jewish Hospital system and at the Infectious Disease Clinical Research Unit at Washington University School of Medicine. The first is the WU-350 study, which is a sample collection study that enrolled participants who were being tested for SARS-CoV-2, and thus, baseline samples consist of both SARS-CoV-2-positive and -negative participants. Participants who test positive for SARS-CoV-2 are subsequently followed at 3, 7, 14, and 28 days and then 3, 6, 9, and 12 months after infection. Blood, saliva, and other biospecimens are collected from these participants where possible. In total, 500 participants were enrolled in WU-350. This cohort consists of 233 women and 267 men, with 314 African-American 177 white, and 9 Asian participants. The second study, WU-353, enrolled participants with PCR-confirmed SARS-CoV-2 infection who were convalescent and had been tested positive at least 14 days prior to the baseline visit. These participants are also followed every 3 months for 2 years. A total of 171 participants were enrolled in this study. Current demographics are 97 women and 73 men and 1 undisclosed, with 154 white participants, 7 Asian, 6 African-American, and 4 with more than one race or unreported. These participants provided samples every 3
months for up to 2 years. We have also enrolled several of these participants in substudies, which collect lymph node or bone marrow biopsy specimens. Information is being collected from both cohorts about symptoms, recurrent infections, and vaccinations (22).

**CITY (PARIS/Miami, FL).** The COVID Immunity Study (CITY) cohort follows high-risk groups such as health care workers and participants from the community, with a target enrollment of 200 participants divided between those with confirmed prior SARS-CoV-2 infection or self-reported as uninfected. The first participant was enrolled on 23 October 2020, and enrollment is complete. As of 18 November 2021, we have recruited 228 participants (39.9% males and 60.1% females) with an average age of 48.2 years (range: min., 20; max., 92 years). A total of 84% of the participants self-identified as white, 6.6% as African-American, 5.2% as Asian, and 3.9% as other. Overall, 38.5% identified as Hispanic/LatinX. SARS-CoV-2 infection status is well matched, with 49.5% (113) having had SARS-CoV-2 infection and 50.5% (115) not ever being SARS-CoV-2 infected. A total of 87.2% (199) of the cohort has received at least one dose of an mRNA-vaccine (BNT162b2 or mRNA-1273) or vectored vaccine (J&J). Based on their real-time study status, only 6% of the SARS-CoV-2-uninfected group and 21.2% of those with past COVID-19 diagnosis have not yet been vaccinated. Participants are followed monthly for the first 6 visits, including baseline, and then every other month for each subsequent visit up to 2 years; 118 participants have completed year 1 and are continuing into year 2. At each visit, serum, plasma, and peripheral blood mononuclear cells are collected and cryopreserved. Overall study withdrawal occurred in 20.2% (46) of participants; of these, 45.6% (21) were in the noninfected and 54.3% (25) in the previously infected group. In addition to the regular follow-ups, we are collecting samples after COVID-19 vaccine and booster doses at two additional time points (1 week and 1 month post-last vaccine dose and booster) to collect plasma, serum, and PBMCs. At present, we have these samples collected from 84 participants.

**SPARTA/Athens.** The SPARTA/Athens study follows university employees and students at the University of Georgia, hospital workers from Piedmont Athens Regional and St. Mary’s Hospitals, first responders, and residents from the local Atlanta, GA, and Athens, GA, communities. The first participant was enrolled on 1 October 2020. As of 28 February 2022, 1,833 participants were enrolled in the study, and enrollment is ongoing. Of the potential participants that completed a study screening call, 1,833 enrolled, 60 declined enrollment, and the enrollment process is ongoing for 10 participants. To date, 114 participants have withdrawn from the study (withdrawal rate, 6.5%). A total of 69% of participants are female, 31% are male, and 0.3% identify as other. The average age is 44.7 years (range: min., 18; max., 86 years); 86% of the participants self-identify as white, 4% as Asian, 7% as African-American, and 2% as other or multiple. In additon, 6% identified as Hispanic/LatinX. A total of 13% of participants were previously infected at enrollment, and 61% were SARS-CoV-2 naive; 74% of the cohort was vaccinated as of 28 February 2022, and 61% were vaccinated without history of infection. A total of 931 participants received the BNT162b2 (Pfizer) vaccine, 383 participants received the mRNA-1273 (Moderna) vaccine, 3 participants received the AZD1222 (AstraZeneca) vaccine, and 29 participants received the Ad26.COV2.S (J&J) vaccine; 42.9% of the entire Athens cohort (786 out of 1,833 total participants) received a vaccine booster. A total of 236 breakthrough infections occurred as of February 2022 in the Athens cohort. Of the Athens/SPARTA participants, 11% (175) are currently antibody negative and 89% (1,559) are antibody positive, largely due to vaccination. There are 33 participants that have tested positive for viral RNA following nasal swab/saliva collection, which amounts to 2% of the Athens/SPARTA cohort. At each visit, saliva, serum, plasma, and peripheral blood mononuclear cells are collected and cryopreserved.

**SPARTA/Augusta.** The SPARTA/Augusta study follows Augusta University Medical Center health care workers and students at the Augusta University, hospital workers from the Dental College of Georgia, and residents from the regional Central Savannah River Area communities. The first participant was enrolled on 12 October 2020. As of 1 April 2022, 637 participants were enrolled in the study, and enrollment is ongoing. To date, 108 participants have formally withdrawn or transferred to another study site. Of
all subjects enrolled, 62.1% are female and 37.9% are male. The average age is ~45 years (range, 18 to 85). A total of 49.1% self-identify as white, 10.7% as Asian, 38.2% as African-American, and 2.6% as other or multiple, and 5.2% identify as Hispanic/LatinX. In addition, 49.9% were previously infected or vaccinated at enrollment, and 51.1% were SARS-CoV-2 naive. 177 participants tested positive at enrollment for viral RNA following nasal swab/saliva collection, which is 30% of the cohort. Currently, 25.4% are antibody negative and 74.1% are antibody positive, largely due to vaccination. At each visit, saliva, serum, plasma, and peripheral blood mononuclear cells are collected and cryopreserved.

**SPARTA/St. Jude.** The SPARTA/St. Jude (SJTRC) study follows hospital employees, with both direct and indirect patient contact, at St. Jude Children’s Research Hospital (SJCRH) in Memphis, TN. The first participant was enrolled on 23 April 2020, and of the potential participants who received the study participation email, 1,316 had enrolled as of 28 February 2022. Enrollment is closed for the naive arm of the study but is ongoing for infected individuals. To date, 80 participants have withdrawn from the study, mostly because they no longer work at SJCRH (withdrawal rate, 6%). In all, 73.4% of participants are female, and 26.3% are male. The average age is 43.7 years (range: min., 20; max., 83 years). A total of 80% of the participants self-identified as white, 9% as Asian, 0.1% as American Indian/Alaska Native, and 2.6% as other or declined to answer. In addition, 3.6% identified as Hispanic/LatinX, and 94.7% identified as non-Hispanic. As of 28 February 2022, of the unvaccinated participants, 6.7% (88) had no infection history, and 2.4% (31) have infection history. Of the vaccinated participants, 77.9% (1,025) have no infection history, 10.6% (139) were infected prior to vaccination, 1.0% (13) were infected during vaccination or 14 days following the full course of vaccination. A total of 1,049 participants received BNT162b2 (Pfizer), 135 participants received mRNA-1273 (Moderna), 17 participants received Ad26.COV2.S (J&J), and 1 participant received multiple vaccines. Of the SJTRC participants with serological tests run, 926 individuals are SARS-CoV-2 receptor binding domain (RBD)- and spike IgG antibody-positive, largely due to vaccination. There are 192 participants that have tested positive for viral RNA following nasal swab/saliva collection, which is 14.6% of the SJTRC cohort. Subjects are routinely swabbed as part of an employee screening program and have consented to have those results and their swabs used for study purposes. Symptomatic screening is also performed. For baseline enrollment, plasma and peripheral blood mononuclear cells are collected and cryopreserved. Following a positive PCR test, plasma and peripheral blood mononuclear cells are collected and cryopreserved at acute (<day 14), convalescent (~day 28), and post-convalescent (every subsequent 3 months) time points. Postvaccine time points (approximately day 14 after completion) are also collected for plasma and peripheral blood mononuclear cells.

**SPARTA/Los Angeles, CA.** The Los Angeles-SPARTA (SPARTA/LA) component of the program is the western-most site of the PARIS/SPARTA network. SPARTA/LA is based at the Lundquist Institute on the Harbor-UCLA Medical Center Campus in southwest Los Angeles County. Participant enrollment was focused on individuals at the intersection of a real-world situation of great concern—high COVID-19 risk and high vaccine hesitancy. In this respect, the recruitment goal was to engage participants likely to have a high risk of SARS-CoV-2 exposure but who represent populations less likely to be vaccinated, including Hispanic/LatinX, Pacific Islanders, and African-American and other underrepresented groups. Participants were enrolled based on results of viral nucleic acid and/or antibody testing and then followed in one of two parallel study cohorts; cohort A followed individuals with documented acute SARS-CoV-2 infection (PCR positive for SARS-CoV-2 RNA) at time of enrollment, and cohort B followed individuals found to be antibody positive due to prior infection or vaccination. The first participant was enrolled on 9 December 2020. As of 28 February 2022, 200 participants were enrolled in the study, and enrollment is complete. To date, 12 participants (6%) have withdrawn from the study. Among enrolled participants, 70%...
are female and 30% are male. The mean age of participants is 40.2 years (range, 19 to 77). Racial/ethnic background was 40.5% Hispanic/Latino, 29% Asian, 16.5% non-Hispanic white, 6.5% African-American, 4% mixed race, 2% Native Hawaiian/Pacific Islander, 0.5% American Indian/Alaskan Native, and 1% other/declined to answer. The vaccination rate in our cohort was 83% as of 28 February 2022; 83% of vaccinated participants received the BNT162b2 (Pfizer) vaccine, 15% received the mRNA-1273 (Moderna) vaccine, and 2% received the Ad26.COV2.S (J&J) vaccine. At enrollment, 18% were antibody negative and 82% were antibody positive (65.5% due to vaccination and 16.5% due to prior SARS-CoV-2 infection). At each study visit, saliva, serum, plasma, and peripheral blood mononuclear cells are collected and cryopreserved.

PARIS/SPARTA INFECTION AND REINFECTION CLASSIFICATION

An important aspect of the PARIS and SPARTA cohorts is the common unified definitions of infection and reinfection, which are applicable both in the pre- as well as postvaccine era. Of note, these temporary working definitions will be continuously refined as we obtain more data from our longitudinal cohorts and as understanding of the immunological and virological dynamics of SARS-CoV-2 infections grows. Our current classification includes distinct categories for seronegative versus seropositive individuals. Factors taken into account are the reliability of diagnostic molecular and serological tests, the time between potential initial infection and reinfection, complete viral genome sequence information, and consistent increase in serum antibody responses. Missing/unobserved data will be taken into account in the future.

SARS-CoV-2 infection in a previously seronegative individual. (i) Possible infection. One positive test including any of the following: nucleic acid amplification test (NAAT), rapid antigen test, or serological test (e.g., SARS-CoV-2 IgM/IgG).

(ii) Confirmed infection. A combination of any two positive tests completed, including molecular tests (NAAT), rapid antigen tests, complete viral genome sequencing, clinical diagnosis of COVID-19, or serological assays used in the study (3, 21). With the exception of complete viral genome sequencing, diagnostic tests must be completed on a different biospecimen.

SARS-CoV-2 infection in a seropositive individual. (established seroconverted due to infection or vaccination). (i) Possible reinfection. Possible reinfections need to meet one of the following scenarios: (i) Two positive molecular tests (NAAT) at least 90 days apart. (ii) A stable (two measurements at a lower level followed by two measurements at a higher level) 4-fold increase in serum spike antibody titer in individuals who are seropositive. (iii) The combination of a documented positive NAAT for the primary infection and evidence for the second infection being caused by a viral strain that did not exist/circulate in a given region at the time of the first infection (and an unlikely within-host descendant of the previously infecting strain) is also considered as representing a likely reinfection.

(ii) Possible breakthrough infection after vaccination. One positive test including any of the following: NAAT, rapid antigen test, or serological test against nucleoprotein.

(iii) Confirmed reinfection. Two NAAT-confirmed SARS-CoV-2 infections in which both viruses were isolated, sequenced, and determined to be phylogenetically distinct to constitute separate infection events.

(iv) Confirmed breakthrough infection after vaccination. A combination of any two positive tests, including molecular tests (NAAT), rapid antigen tests, complete viral genome sequencing conducted on a different biospecimen, serological test against nucleoprotein, or clinical diagnosis of COVID-19. A change in antibody levels after the infection is also indicative of an infection. Of note, individuals who are seropositive exclusively due to vaccination, will not develop antibodies to regions other than spike (e.g., N protein).

DISCUSSION

We established the PARIS and SPARTA cohorts to study infection with SARS-CoV-2 in seropositive and seronegative participants at high risk for infection. In addition to
defining the durability and variability of antibody responses, we seek to obtain data on
the attack rates in both groups, which will inform about the risk of reinfection and help
identify the spike antibody titers that correlate with protection in individuals with dif-
ferent histories of exposure to SARS-CoV-2.

The data collected across the studies (some of which started as early as March/April
2020) will provide insights into infection and reinfection with SARS-CoV-2 (23–30) in
naive and vaccinated participants, including by variants of concern, once the ongoing
analysis is completed.

Many of the PARIS/SPARTA participants are health care workers, who were first in
line to be eligible for SARS-CoV-2 vaccination starting in December 2020 and who
were also first in line for booster doses in 2021. Thus, vaccination rates in several of the
cohorts increased rapidly leading to the conversion of the initial natural infection stud-
ies to studies that are suited to characterize the protective effects of vaccines, includ-
ing immune responses mounted to vaccination in naive individuals and individuals
who previously had COVID-19, immune responses to booster doses and breakthrough
infections as well as vaccine-induced correlates of protection (31, 32). With the emer-
gence of viral variants of interest/concern, the PARIS/SPARTA cohorts started also to
characterize viruses isolated from participants infected after vaccination to determine
if viral variants carrying mutations indicative of immune escape are present. To date,
data and samples from PARIS/SPARTA have already been used in several studies,
including work that determined that only one SARS-CoV-2 mRNA vaccine shot may be
necessary in individuals previously infected with COVID-19 (see references to PARIS/
SPARTA manuscripts in Table 1). The data collected from PARIS/SPARTA participants
also have value as a healthy control group, which can be used as a reference when
analyzing immune responses observed in patient populations with specific immune-
modulatory comorbidities (e.g., posttransplant patients, patients with B cell malignan-
cies, or patients receiving treatment with biologicals) (33, 34). In addition, cohort sam-
ple have been a rich source to study the longevity of infection-induced B-cells in the
bone marrow, to study affinity maturation of B-cells after COVID-19 vaccination, to
c characterize the T-cell response to SARS-CoV-2, etc., and similar studies using PARIS/
SPARTA samples are ongoing (22, 35, 36). Currently, samples from PARIS/SPARTA are
being extensively used to determine immune responses after booster doses and after
breakthrough infections, and assessment of mucosal immune responses in the cohorts
is also ongoing (37). Furthermore, samples from the PARIS/SPARTA cohorts have been
shared with and used extensively by the SARS-CoV-2 Assessment of Viral Evolution
(SAVE) program (38), which was established by the National Institutes of Health to track
and characterize variants of concern (39, 40). SAVE investigators have used these sam-
ples to track immune escape of different variants from neutralizing antibodies (38).

This study design is unique in that it encompasses eight geographically distinct
cohorts exploring specific aspects of viral infections and vaccination using harmonized
assays and analysis, which allows for pooling of data from many study participants for
robust secondary analysis. However, one limitation is, that the study population con-
ists of mostly health care workers and is in general healthy and younger, with individ-
uals with comorbidities being underrepresented. In the near future, the PARIS/SPARTA
cohorts will be uniquely suited to track the kinetics of and protection afforded by vac-
cine-induced immunity over time, including against novel viral variants, and to investi-
gate how vaccination influences postacute sequelae of COVID-19 (PASC, long COVID-
19).

ACKNOWLEDGMENTS

We thank the study participants for their continued generosity and willingness to
support COVID-19 research. We thank Teresa Hauguel, Stacy Ferguson, Debbie Bratt,
and Diane Post at NIAID for their scientific input and encouragement during these
challenging times.

This work is part of the PARIS/SPARTA studies funded by the NIAID Collaborative Influenza
Vaccine Innovation Centers (CIVIC) contracts 75N93019C00051 and 75N93019C00052. T.M.R.
supported by the Georgia Research Alliance as an eminent scholar. We also thank the University of Georgia Clinical and Translational Research Unit (CTRU) for assistance. The CTRU is supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under award number UL1TR002378. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. SPARTA LA was also supported by the UCLA W. M. Keck Foundation COVID-19 Research Award Program.

The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays (named inventors, F.K. and V.S.) and Newcastle disease virus-based SARS-CoV-2 vaccines (named inventor, F.K.). F.K. also notes the following, which could be perceived as a conflict of interest: He has previously published work on influenza virus vaccines with S. Gilbert (University of Oxford), has consulted for Curevac, Merck, and Pfizer (before 2020), is currently consulting for Pfizer, Seqirus, Third Rock Ventures, and Avimex; his laboratory is collaborating with Pfizer on animal models for SARS-CoV-2, his laboratory is collaborating with N. Pardi at the University of Pennsylvania on mRNA vaccines against SARS-CoV-2, his laboratory was working in the past with GlaxoSmithKline on the development of influenza virus vaccines, and three of his mentees have recently joined Moderna. R.K. reports consulting fees, honoraria, travel funding, and research support from Illumina, Qiagen, and Perkin Elmer, which manufactures SARS-CoV-2 testing and sequencing kits.


REFERENCES


